Exozymes Inc. SEC filings EXOZ
Exozymes Inc. has 128 filings in SEC EDGAR's recent list, going back to Feb 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Sep 28, 2026 | — |
| DEF 14A | Proxy statement | Sep 28, 2026 | Nov 13, 2026 |
| DEF 14A | Proxy statement | Jun 20, 2025 | Jul 25, 2025 |
Showing 3 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXOZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Monrovia, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2010788
- Former names
- Invizyne Technologies Inc (until Jan 21, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.